T2 Biosystems to Participate in the Canaccord Genuity Virtual MedTech & Diagnostics Forum
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid
detection of sepsis-causing pathogens, today announced that the
Company plans to participate in the upcoming Canaccord Genuity
Virtual MedTech & Diagnostics Forum.
Management is scheduled to present Thursday, November 19, 2020
at 2:30pm ET. Interested parties may access a live and recorded
webcast of the presentation on the “Investors” section of the
Company’s website at www.t2biosystems.com.
About T2 BiosystemsT2 Biosystems, a leader
in the rapid detection of sepsis-causing pathogens, is dedicated to
improving patient care and reducing the cost of care by helping
clinicians effectively treat patients faster than ever before. T2
Biosystems’ products include the T2Dx® Instrument, T2Candida®
Panel, the T2Bacteria® Panel, the T2Resistance® Panel, and the
T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic
Resonance (T2MR®) technology. T2 Biosystems has an active pipeline
of future products, including the T2Cauris™ Panel, and T2Lyme™
Panel, as well as additional products for the detection of
bacterial and fungal pathogens and associated antimicrobial
resistance markers, and biothreat pathogens.
Media Contact:Gina Kent, Vault
Investor Contact:Philip Trip Taylor, Gilmartin